Literature DB >> 20012313

Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7.

A Ben Ammar1, F Petit, N Alexandri, K Gaudon, S Bauché, A Rouche, D Gras, E Fournier, J Koenig, T Stojkovic, A Lacour, P Petiot, F Zagnoli, L Viollet, N Pellegrini, D Orlikowski, L Lazaro, X Ferrer, G Stoltenburg, M Paturneau-Jouas, F Hentati, M Fardeau, D Sternberg, D Hantaï, P Richard, B Eymard.   

Abstract

Congenital myasthenic syndromes (CMSs) are a heterogeneous group of diseases caused by genetic defects affecting neuromuscular transmission. Mutations of DOK7 have recently been described in recessive forms of CMS. Dok-7 is a cytoplasmic post-synaptic protein co-activator of the muscle-specific receptor-tyrosine kinase (MuSK) involved in neuromuscular synaptogenesis and maintenance. We report clinical, morphological and molecular data on 15 patients with mutations in DOK7. Eleven different mutations (5 novel) were identified and all patients but one were found to carry at least the common c.1124_1127dupTGCC mutation. Patients with DOK7 mutations have a particular limb-girdle pattern, without tubular aggregates but a frequent lipidosis on the muscle biopsy. Changes in pre- and post-synaptic compartments of the neuromuscular junction were also observed in muscle biopsies: terminal axons showed defective branching which resulted in a unique terminal axon contacting en passant postsynaptic cups. Clinical features, muscle biopsy findings or response to therapy were confusing in several patients. Characterization of this distinct phenotype is essential to provide clues for targeted genetic screening and to predict the therapeutic response to anticholinesterase treatments or ephedrine as has been suggested.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20012313     DOI: 10.1007/s00415-009-5405-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Limb-girdle myasthenia: clinical, electrophysiological and morphological features in familial and autoimmune cases.

Authors:  C Rodolico; A Toscano; M Autunno; S Messina; C Nicolosi; M Aguennouz; M Laurà; P Girlanda; C Messina; G Vita
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

Review 2.  Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission.

Authors:  Juliane S Müller; Violeta Mihaylova; Angela Abicht; Hanns Lochmüller
Journal:  Expert Rev Mol Med       Date:  2007-08-09       Impact factor: 5.600

3.  Dok-7 activates the muscle receptor kinase MuSK and shapes synapse formation.

Authors:  Akane Inoue; Kiyoko Setoguchi; Yosuke Matsubara; Kumiko Okada; Nozomi Sato; Yoichiro Iwakura; Osamu Higuchi; Yuji Yamanashi
Journal:  Sci Signal       Date:  2009-02-24       Impact factor: 8.192

4.  A histochemical method for localizing cholinesterase activity.

Authors:  G B KOELLE; J A FRIEDENWALD
Journal:  Proc Soc Exp Biol Med       Date:  1949-04

5.  Some comments on the histochemical characterization of muscle adenosine triphosphatase.

Authors:  M H Brooke; K K Kaiser
Journal:  J Histochem Cytochem       Date:  1969-06       Impact factor: 2.479

6.  MUSK, a new target for mutations causing congenital myasthenic syndrome.

Authors:  Frédéric Chevessier; Brice Faraut; Aymeric Ravel-Chapuis; Pascale Richard; Karen Gaudon; Stéphanie Bauché; Cassandra Prioleau; Ruth Herbst; Evelyne Goillot; Christine Ioos; Jean-Philippe Azulay; Shahram Attarian; Jean-Paul Leroy; Emmanuel Fournier; Claire Legay; Laurent Schaeffer; Jeanine Koenig; Michel Fardeau; Bruno Eymard; Jean Pouget; Daniel Hantaï
Journal:  Hum Mol Genet       Date:  2004-10-20       Impact factor: 6.150

Review 7.  What have we learned from the congenital myasthenic syndromes.

Authors:  Andrew G Engel; Xin-Ming Shen; Duygu Selcen; Steven M Sine
Journal:  J Mol Neurosci       Date:  2009-08-18       Impact factor: 3.444

8.  Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes.

Authors:  Violeta Mihaylova; Juliane S Müller; Juan J Vilchez; Mustafa A Salih; Mohammad M Kabiraj; Adele D'Amico; Enrico Bertini; Joachim Wölfle; Felix Schreiner; Gerhard Kurlemann; Vedrana Milic Rasic; Dana Siskova; Jaume Colomer; Agnes Herczegfalvi; Katarina Fabriciova; Bernhard Weschke; Rosana Scola; Friederike Hoellen; Ulrike Schara; Angela Abicht; Hanns Lochmüller
Journal:  Brain       Date:  2008-01-07       Impact factor: 13.501

9.  Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'.

Authors:  C R Slater; P R W Fawcett; T J Walls; P R Lyons; S J Bailey; D Beeson; C Young; D Gardner-Medwin
Journal:  Brain       Date:  2006-08       Impact factor: 13.501

10.  Clinical features of the DOK7 neuromuscular junction synaptopathy.

Authors:  Jacqueline Palace; Daniel Lashley; John Newsom-Davis; Judy Cossins; Susan Maxwell; Robin Kennett; Sandeep Jayawant; Yuji Yamanashi; David Beeson
Journal:  Brain       Date:  2007-04-23       Impact factor: 13.501

View more
  14 in total

1.  Mutations in GFPT1-related congenital myasthenic syndromes are associated with synaptic morphological defects and underlie a tubular aggregate myopathy with synaptopathy.

Authors:  Stéphanie Bauché; Geoffroy Vellieux; Damien Sternberg; Marie-Joséphine Fontenille; Elodie De Bruyckere; Claire-Sophie Davoine; Guy Brochier; Julien Messéant; Lucie Wolf; Michel Fardeau; Emmanuelle Lacène; Norma Romero; Jeanine Koenig; Emmanuel Fournier; Daniel Hantaï; Nathalie Streichenberger; Veronique Manel; Arnaud Lacour; Aleksandra Nadaj-Pakleza; Sylvie Sukno; Françoise Bouhour; Pascal Laforêt; Bertrand Fontaine; Laure Strochlic; Bruno Eymard; Frédéric Chevessier; Tanya Stojkovic; Sophie Nicole
Journal:  J Neurol       Date:  2017-07-15       Impact factor: 4.849

2.  Pathogenic Abnormal Splicing Due to Intronic Deletions that Induce Biophysical Space Constraint for Spliceosome Assembly.

Authors:  Samantha J Bryen; Himanshu Joshi; Frances J Evesson; Cyrille Girard; Roula Ghaoui; Leigh B Waddell; Alison C Testa; Beryl Cummings; Susan Arbuckle; Nicole Graf; Richard Webster; Daniel G MacArthur; Nigel G Laing; Mark R Davis; Reinhard Lührmann; Sandra T Cooper
Journal:  Am J Hum Genet       Date:  2019-08-22       Impact factor: 11.025

Review 3.  Current status of the congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-11-21       Impact factor: 4.296

Review 4.  Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.

Authors:  Andrew G Engel; Xin-Ming Shen; Duygu Selcen; Steven M Sine
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

5.  Neuromuscular disorders and 2010: recent advances.

Authors:  Anna Sarkozy; Hanns Lochmüller
Journal:  J Neurol       Date:  2010-09-18       Impact factor: 4.849

Review 6.  Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

Authors:  Charlotte Vrinten; Angeli M van der Zwaag; Stephanie S Weinreich; Rob J P M Scholten; Jan J G M Verschuuren
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

7.  Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction.

Authors:  Ricardo A Maselli; Juan Arredondo; Orla Cagney; Jarae J Ng; Jennifer A Anderson; Colette Williams; Bae J Gerke; Betty Soliven; Robert L Wollmann
Journal:  Hum Mol Genet       Date:  2010-04-06       Impact factor: 6.150

8.  Pregnancy in congenital myasthenic syndrome.

Authors:  L Servais; H Baudoin; K Zehrouni; P Richard; D Sternberg; E Fournier; B Eymard; T Stojkovic
Journal:  J Neurol       Date:  2012-10-30       Impact factor: 4.849

9.  Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations.

Authors:  Velina Guergueltcheva; Juliane S Müller; Marina Dusl; Jan Senderek; Anders Oldfors; Christopher Lindbergh; Susan Maxwell; Jaume Colomer; Cecilia Jimenez Mallebrera; Andres Nascimento; Juan J Vilchez; Nuria Muelas; Janbernd Kirschner; Shahriar Nafissi; Ariana Kariminejad; Yalda Nilipour; Bita Bozorgmehr; Hossein Najmabadi; Carmelo Rodolico; Jörn P Sieb; Beate Schlotter; Benedikt Schoser; Ralf Herrmann; Thomas Voit; Ortrud K Steinlein; Abdolhamid Najafi; Andoni Urtizberea; Doriette M Soler; Francesco Muntoni; Michael G Hanna; Amina Chaouch; Volker Straub; Kate Bushby; Jacqueline Palace; David Beeson; Angela Abicht; Hanns Lochmüller
Journal:  J Neurol       Date:  2011-10-06       Impact factor: 4.849

10.  KLHL40-related nemaline myopathy with a sustained, positive response to treatment with acetylcholinesterase inhibitors.

Authors:  D Natera-de Benito; A Nascimento; A Abicht; C Ortez; C Jou; J S Müller; T Evangelista; A Töpf; R Thompson; C Jimenez-Mallebrera; J Colomer; H Lochmüller
Journal:  J Neurol       Date:  2016-01-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.